# Prescribed TB-500 contact information

> Correspondence on Prescribed TB-500 — Prescribed TB-500 contact information and research corrections: the exact sentence, the study and the disputed finding. No published inbox is currently listed.

**Corrections and correspondence**

A correction is most useful when it identifies a sentence and the published evidence that puts it in doubt.

## The sentence, the source and the disputed noun

For a TB-500 source correction, the useful particulars are the page, the sentence and the paper. A wrong compound name is different from a wrong animal, an overstated outcome or a study amount mistaken for a recommendation. The distinction affects what needs to change.

A source-backed objection to my argument is welcome, too. Evidence that the fragment retains a particular parent-protein activity would matter; it would not automatically settle every other proposed activity. The [reading list](/references) identifies the papers presently discussed.

There is no published inbox or working contact form on this site at present. I cannot promise delivery of a message without a destination for it. This page records the contact limitation plainly instead of presenting an unusable form.

## Correspondence cannot examine an injury

An editorial correction cannot establish whether TB-500 is appropriate for a person, supply an amount, assess a preparation's purity or decide a pharmacy's legal position. Those matters require the relevant licensed professional and the person's circumstances.

The [about page](/about) explains the site. For a disputed factual claim, the [published sources](/references) are the place to begin.

---

A developer-console reading of the TB-500 record — the actin-binding fragment logged against its studies, with the full-length thymosin beta-4 caveat flagged in every diff, no clinic behind the terminal and nothing here prescribed or sold.